@Article{,
AUTHOR = {Vivian Barak, Inna Kalickman, Tal Halperin, Shlomo Birkenfeld, Isaac Ginsburg},
TITLE = {PADMA-28, A Tibetan herbal preparation is an inhibitor of inflammatory cytokine production},
JOURNAL = {European Cytokine Network},
VOLUME = {15},
YEAR = {2004},
NUMBER = {3},
PAGES = {203--209},
URL = {http://www.techscience.com/ECN/v15n3/66375},
ISSN = {1952-4005},
ABSTRACT = {Background: Previous studies have shown that PADMA-28, a multicomponent, traditional Tibetan
herbal plant preparation possesses a variety of beneficial effects on several experimental models of inflammatory
and immune processes, including autoimmune diabetes and autoimmune encephalomyelitis. In humans,
PADMA-28 attenuated the symptoms associated with intermittent claudications in atherosclerotic patients.
Objective: To assess the effect of PADMA 28 on the immune system, e.g. cytokine (interleukins) production.
Design: Cytokine production by human blood monocytes (derived from12 healthy donors) stimulated in vitro,
either by endotoxin (LPS) from Salmonella typhi or by lipoteichoic acid (LTA) from group A Streptococci was
modulated by PADMA-28. Results: The present study showed that an aqueous extract of PADMA-28 strongly
decreased the production of the inflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α, and more moderately, also
decreased the anti-inflammatory cytokine IL-10 induced by LPS. However, the LTA - induced IL-10 production
was [not significantly] increased by the low dose PADMA-28, while not effected at all by the higher dose of
PADMA-28. Conclusions: The data from these finding suggest a possible clinical efficacy of PADMA-28 either in
autoimmune and in inflammatory conditions or in post-inflammatory sequelae, as previously shown in in vivo and
human studies, probably by decreasing inflammatory cytokines.},
DOI = {}
}